Lmcg Investments LLC Makes New $2.32 Million Investment in Baxter International Inc. $BAX

Lmcg Investments LLC purchased a new stake in Baxter International Inc. (NYSE:BAX) in the third quarter, Holdings Channel.com reports. The institutional investor purchased 96,793 shares of the medical instruments supplier’s stock, valued at approximately $2,323,000.

Several other institutional investors have also recently made changes to their positions in BAX. BlackRock Inc. acquired a new position in shares of Baxter International in the 2nd quarter valued at $1,744,874,000. Pzena Investment Management LLC purchased a new stake in Baxter International during the second quarter worth $1,392,098,000. Equity Investment Corp acquired a new stake in Baxter International during the second quarter valued at $146,815,000. Bank of America Corp DE acquired a new stake in Baxter International during the second quarter valued at $132,993,000. Finally, Bank of New York Mellon Corp purchased a new position in Baxter International in the second quarter valued at $68,036,000. 90.19% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Stifel Nicolaus upped their price objective on shares of Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a research report on Tuesday, July 28th. Citigroup dropped their target price on Baxter International from $28.00 to $27.00 and set a “neutral” rating on the stock in a research report on Monday, October 5th. Zacks Research upgraded Baxter International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. TD Cowen lifted their price target on Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a research note on Monday, July 27th. Finally, Wolfe Research initiated coverage on Baxter International in a report on Tuesday. They issued a “peer perform” rating for the company. One research analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $21.73.

Baxter International Trading Up 1.0%

Shares of BAX stock opened at $24.74 on Thursday. Baxter International Inc. has a 1-year low of $15.73 and a 1-year high of $30.00. The company has a market cap of $12.79 billion, a price-to-earnings ratio of -11.95, a PEG ratio of 3.71 and a beta of 0.65. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32. The stock has a 50 day simple moving average of $24.81 and a 200-day simple moving average of $22.06.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%. The firm had revenue of $2.96 billion for the quarter, compared to analyst estimates of $2.80 billion. During the same quarter last year, the firm posted $0.59 EPS. The business’s revenue was up 5.3% on a year-over-year basis. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. On average, equities research analysts expect that Baxter International Inc. will post 2.04 EPS for the current fiscal year.

Baxter International Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 1st. Shareholders of record on Friday, August 28th were given a dividend of $0.01 per share. The ex-dividend date was Friday, August 28th. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. Baxter International’s dividend payout ratio is currently -1.93%.

Baxter International Profile

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter’s portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.